Literature DB >> 581029

Unaltered metabolism of phenytoin in thyroid disorders.

J Mølholm Hansen, L Skovsted, J P Kampmann, B I Lumholtz, K Siersbaek-Nielsen.   

Abstract

The metabolism of phenytoin was studied in 9 hyperthyroid and 7 hypothyroid patients before and after treatment with either antithyroid drugs or 1-thyroxine. No difference in the half-life, volume of distribution and metabolic clearance rate was found between untreated hyper- and hypothyroid subjects. Furthermore, normalisation of thyroid function test did not change the kinetic parameters of phenytoin. The results indicate that the well-known correlation between thyroid function and antipyrine kinetics cannot be extrapolated uncritically to other drugs. It is concluded that no general rules are valid in the kinetics among different drugs in thyroid pathological conditions. Each drug must be evaluated by itself in different pathological conditions.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 581029     DOI: 10.1111/j.1600-0773.1978.tb02214.x

Source DB:  PubMed          Journal:  Acta Pharmacol Toxicol (Copenh)        ISSN: 0001-6683


  7 in total

1.  Differential effect of continuous administration of beta-adrenoceptor antagonists on antipyrine and phenytoin clearance.

Authors:  H Perrild; L Kayser; H E Poulsen; L Skovsted; B Jørgensen; J M Hansen
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

Review 2.  Influence of thyroid dysfunction on drug pharmacokinetics.

Authors:  G M Shenfield
Journal:  Clin Pharmacokinet       Date:  1981 Jul-Aug       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics and endocrine disorders. Therapeutic implications.

Authors:  P O'Connor; J Feely
Journal:  Clin Pharmacokinet       Date:  1987-12       Impact factor: 6.447

4.  Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism.

Authors:  J Sonne; S Boesgaard; H E Poulsen; S Loft; J M Hansen; M Døssing; F Andreasen
Journal:  Br J Clin Pharmacol       Date:  1990-11       Impact factor: 4.335

5.  Oxazepam pharmacokinetics in thyroid disease.

Authors:  A K Scott; A S Khir; P D Bewsher; G M Hawksworth
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

Review 6.  Clinical pharmacokinetics of antithyroid drugs.

Authors:  J P Kampmann; J M Hansen
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

7.  Pharmacokinetics and pharmacodynamics of propranolol stereoisomers in hyperthyroid patients.

Authors:  K Tawara; K Kawashima; H Ishikawa; K Yamamoto; K Saito; A Ebihara; S Yoshida
Journal:  Eur J Clin Pharmacol       Date:  1981-02       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.